Redtail
2021-12-01
If true good for all :)
BioNTech CEO says vaccine likely to protect against severe COVID from Omicron
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609794382,"tweetId":"609794382","gmtCreate":1638323592218,"gmtModify":1638323592218,"author":{"id":4099729092893840,"idStr":"4099729092893840","authorId":4099729092893840,"authorIdStr":"4099729092893840","name":"Redtail","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>If true good for all :) </p></body></html>","htmlText":"<html><head></head><body><p>If true good for all :) </p></body></html>","text":"If true good for all :)","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609794382","repostId":2188853699,"repostType":4,"repost":{"id":"2188853699","kind":"news","pubTimestamp":1638320100,"share":"https://www.laohu8.com/m/news/2188853699?lang=&edition=full","pubTime":"2021-12-01 08:55","market":"us","language":"en","title":"BioNTech CEO says vaccine likely to protect against severe COVID from Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2188853699","media":"StreetInsider","summary":"BioNTech and Pfizer's established COVID-19 vaccine will likely offer strong protection against any s","content":"<p>BioNTech and Pfizer's established COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech's Chief Executive told Reuters.</p>\n<p>Lab tests are underway over the next two weeks to analyse the blood of people who had two or three doses of BioNTech's Comirnaty vaccine to see if antibodies found in that blood inactivate Omicron, potentially shedding light on whether new vaccines are needed.</p>\n<p>\"We think it's likely that people will have substantial protection against severe disease caused by Omicron,\" said BioNTech CEO and co-founder Ugur Sahin. He specified severe disease as requiring hospital or intensive care.</p>\n<p>Sahin told Reuters he expects the lab tests to show some loss of vaccine protection against mild and moderate disease due to Omicron, but the extent of that loss was hard to predict.</p>\n<p>The biotech firm is speedily working on an upgraded version of its vaccine, although it remains unclear whether that is needed, he added.</p>\n<p>Sahin said getting a third vaccine shot known as booster will likely confer a layer of protection against Omicron infection of any severity compared to those with just the initial two-shot course.</p>\n<p>\"To my mind there's no reason to be particularly worried. The only thing that worries me at the moment is the fact that there are people that have not been vaccinated at all,\" Sahin added.</p>\n<p>BioNTech's guarded confidence contrasts with a sense of alarm conveyed by the chief executive of rival vaccine maker Moderna, Stephane Bancel.</p>\n<p>In a Financial Times interview, he raised the prospect of a material drop in protection against the new coronavirus lineage from current vaccines, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech CEO says vaccine likely to protect against severe COVID from Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech CEO says vaccine likely to protect against severe COVID from Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 08:55 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=19288893><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech and Pfizer's established COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech's Chief Executive told Reuters.\nLab tests...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19288893\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19288893","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188853699","content_text":"BioNTech and Pfizer's established COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech's Chief Executive told Reuters.\nLab tests are underway over the next two weeks to analyse the blood of people who had two or three doses of BioNTech's Comirnaty vaccine to see if antibodies found in that blood inactivate Omicron, potentially shedding light on whether new vaccines are needed.\n\"We think it's likely that people will have substantial protection against severe disease caused by Omicron,\" said BioNTech CEO and co-founder Ugur Sahin. He specified severe disease as requiring hospital or intensive care.\nSahin told Reuters he expects the lab tests to show some loss of vaccine protection against mild and moderate disease due to Omicron, but the extent of that loss was hard to predict.\nThe biotech firm is speedily working on an upgraded version of its vaccine, although it remains unclear whether that is needed, he added.\nSahin said getting a third vaccine shot known as booster will likely confer a layer of protection against Omicron infection of any severity compared to those with just the initial two-shot course.\n\"To my mind there's no reason to be particularly worried. The only thing that worries me at the moment is the fact that there are people that have not been vaccinated at all,\" Sahin added.\nBioNTech's guarded confidence contrasts with a sense of alarm conveyed by the chief executive of rival vaccine maker Moderna, Stephane Bancel.\nIn a Financial Times interview, he raised the prospect of a material drop in protection against the new coronavirus lineage from current vaccines, sparking fresh worry in financial markets about the trajectory of the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":457,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":18,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609794382"}
精彩评论